Who
Kathleen Sebelius
Director
Company insider
Files Form 4 as: Director, Humacyte; Director, Exact Sciences; Director, Myovant Sciences; Director, Dermira.
In numbers
- Trades disclosed
- 57
- Buys
- 3
- Sells
- 1
- Bought
- $211K
- Sold
- $28K
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 30 Sep 2015
- Last trade
- 11 Jun 2026
- Last filed
- 12 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Jun 2026filed 12 Jun 2026 | HUMA Humacyteoption or derivative · Biotechnology | SEC FORM 4 Code A | —80,000 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | HUMA Humacyteoption or derivative · Biotechnology | SEC FORM 4 Code A | —80,000 at $0.00 | filing |
| 19 May 2026filed 20 May 2026 | HUMA HumacyteBiotechnology | SEC FORM 4 Bought | $50K56,818 at $0.88 | filing |
| 19 May 2026filed 20 May 2026 | HUMA HumacyteBiotechnology | SEC FORM 4 Bought | $50K56,818 at $0.88 | filing |
| 12 Jun 2025filed 16 Jun 2025 | HUMA Humacyteoption or derivative · Biotechnology | SEC FORM 4 Code A | —80,000 at $0.00 | filing |
| 8 Apr 2025filed 8 Apr 2025 | HUMA HumacyteBiotechnology | SEC FORM 4 Bought | $66K50,000 at $1.32 | filing |
| 10 Sep 2024filed 11 Sep 2024 | HUMA Humacyteoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,521 at $0.00 | filing |
| 10 Sep 2024filed 11 Sep 2024 | HUMA Humacyteoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,479 at $0.00 | filing |
| 10 Sep 2024filed 11 Sep 2024 | HUMA HumacyteBiotechnology | SEC FORM 4 Code M | $20K4,521 at $4.34 | filing |
| 10 Sep 2024filed 11 Sep 2024 | HUMA HumacyteBiotechnology | SEC FORM 4 Sold | $20K3,634 at $5.41 | filing |
| 10 Sep 2024filed 11 Sep 2024 | HUMA HumacyteBiotechnology | SEC FORM 4 Code M | $8,3052,479 at $3.35 | filing |
| 10 Sep 2024filed 11 Sep 2024 | HUMA HumacyteBiotechnology | SEC FORM 4 Sold | $8,3441,548 at $5.39 | filing |
| 14 Jun 2024filed 17 Jun 2024 | HUMA Humacyteoption or derivative · Biotechnology | SEC FORM 4 Code M | —39,389 at $0.00 | filing |
| 14 Jun 2024filed 17 Jun 2024 | HUMA HumacyteBiotechnology | SEC FORM 4 Code M | $101K39,389 at $2.56 | filing |
| 13 Jun 2024filed 20 Dec 2024 | Exact Sciences | SEC FORM 4 Code A | —7,672 at $0.00 | filing |
| 13 Jun 2024filed 17 Jun 2024 | Exact Sciences | SEC FORM 4 Code A | —6,889 at $0.00 | filing |
| 13 Jun 2024filed 17 Jun 2024 | HUMA Humacyteoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 15 Jun 2023filed 16 Jun 2023 | HUMA Humacyteoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,500 at $0.00 | filing |
| 8 Jun 2023filed 12 Jun 2023 | Exact Sciences | SEC FORM 4 Code A | —3,599 at $0.00 | filing |
| 9 Jun 2022filed 13 Jun 2022 | Exact Sciences | SEC FORM 4 Code A | —7,523 at $0.00 | filing |
News
Humacyte Provides Commercial Update and Highlights Rapid Acceleration of Symvess Adoption by HospitalsHUMA · manilatimes.net · 15 Oct 2026
0 headlines in the last 90 days name Kathleen Sebelius; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.